PortfoliosLab logoPortfoliosLab logo
ACRS vs. SGMO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ACRS vs. SGMO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Aclaris Therapeutics, Inc. (ACRS) and Sangamo Therapeutics, Inc. (SGMO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


ACRS

1D
-2.26%
1M
-6.47%
6M
48.15%
YTD
72.76%
1Y
239.87%
3Y*
-19.07%
5Y*
-19.02%
10Y*
-12.11%
ALL TIME*
-7.40%

SGMO

1D
1M
6M
YTD
1Y
3Y*
5Y*
10Y*
ALL TIME*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$8.58M$9.53M$8.25M

ACRS vs. SGMO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ACRS
Aclaris Therapeutics, Inc.
72.76%21.37%136.19%-93.33%8.32%124.73%242.33%-74.42%-70.03%-9.14%
SGMO
Sangamo Therapeutics, Inc.
-82.38%-58.82%87.74%-82.70%-58.13%-51.94%86.44%-27.09%-30.00%437.70%

Correlation

The correlation between ACRS and SGMO is 0.17, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.17

Correlation (3Y)
Balances recent behavior with more history.

0.24

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.32

Correlation (10Y)
Provides a long-term view across more market conditions.

0.28

Correlation (All Time)
Calculated using the full available price history since Oct 7, 2015

0.28

The correlation between ACRS and SGMO shifts across timeframes, from 0.17 (1 year) to 0.32 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

ACRS:

$726.25M

SGMO:

$30.66M

EPS

ACRS:

-$0.56

SGMO:

-$0.36

PS Ratio

ACRS:

77.50

SGMO:

0.74

Total Revenue (TTM)

ACRS:

$8.37M

SGMO:

$34.56M

Gross Profit (TTM)

ACRS:

$6.39M

SGMO:

$25.51M

EBITDA (TTM)

ACRS:

-$73.08M

SGMO:

-$106.29M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ACRS vs. SGMO — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

ACRS
ACRS Risk / Return Rank: 9696
Overall Rank
ACRS Sharpe Ratio Rank: 9595
Sharpe Ratio Rank
ACRS Sortino Ratio Rank: 9696
Sortino Ratio Rank
ACRS Omega Ratio Rank: 9494
Omega Ratio Rank
ACRS Calmar Ratio Rank: 9797
Calmar Ratio Rank
ACRS Martin Ratio Rank: 9797
Martin Ratio Rank

SGMO

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

ACRS vs. SGMO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Aclaris Therapeutics, Inc. (ACRS) and Sangamo Therapeutics, Inc. (SGMO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ACRSSGMODifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

1.45

Calmar ratioReturn relative to maximum drawdown

6.59

Martin ratioReturn relative to average drawdown

18.05

ACRS vs. SGMO - Sharpe Ratio Comparison


Loading charts...

Drawdowns

ACRS vs. SGMO - Drawdown Comparison


Loading charts...

Drawdown Indicators


ACRSSGMODifference

Max Drawdown

Largest peak-to-trough decline

-98.05%

Max Drawdown (1Y)

Largest decline over 1 year

-36.64%

Max Drawdown (3Y)

Largest decline over 3 years

-93.45%

Max Drawdown (5Y)

Largest decline over 5 years

-96.57%

Max Drawdown (10Y)

Largest decline over 10 years

-98.05%

Current Drawdown

Current decline from peak

-84.24%

Average Drawdown

Average peak-to-trough decline

-63.91%

Ulcer Index

Depth and duration of drawdowns from previous peaks

13.35%

Volatility

ACRS vs. SGMO - Volatility Comparison


Loading charts...

Volatility by Period


ACRSSGMODifference

Volatility (1M)

Calculated over the trailing 1-month period

14.22%

Volatility (6M)

Calculated over the trailing 6-month period

44.25%

Volatility (1Y)

Calculated over the trailing 1-year period

96.44%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

92.32%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

110.39%

Dividends

ACRS vs. SGMO - Dividend Comparison

Neither ACRS nor SGMO has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ACRS vs. SGMO - Financials Comparison

This section allows you to compare key financial metrics between Aclaris Therapeutics, Inc. and Sangamo Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


ACRS and SGMO have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for ACRS and SGMO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer